Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789356 | 1.00 | SMPD1 (0.46) | SMPD1LMNAMAPK1HTTTSHR | |
| SCHEMBL2880826 | 0.87 | PLK1 (0.41) | PLK1CNR2 | |
| SCHEMBL2880829 | 0.87 | PLK1 (0.41) | PLK1CNR2 | |
| SCHEMBL36667 | 0.83 | CA2 (0.42) | — | |
| SCHEMBL36666 | 0.83 | CA2 (0.42) | — | |
| SCHEMBL4361332 | 0.82 | ALDH1A1 (0.48) | LMNAHTTTSHRPDE4APDE4B | |
| SCHEMBL4361330 | 0.82 | ALDH1A1 (0.48) | LMNAHTTTSHRPDE4APDE4B | |
| SCHEMBL7781708 | 0.82 | PDE4A (0.47) | LMNAKMT2APDE4APDE4BPDE4C | |
| SCHEMBL7781706 | 0.82 | PDE4A (0.47) | LMNAKMT2APDE4APDE4BPDE4C | |
| SCHEMBL7781699 | 0.82 | CA2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | claimed |
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | disclosed |
| US-6017675-A | POLYMERIZATION CATALYST | CIBA SPECIALTY CHEMIALS CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | QSOX1, HAO2, PAH | SMPD1 2253/4885LMNA 624/4885MAPK1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.